Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations (2021 - 2025)

Historic Cash from Operations for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.4 million.

  • InMed Pharmaceuticals' Cash from Operations rose 503.15% to -$2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.4 million, marking a year-over-year decrease of 177.48%. This contributed to the annual value of -$7.8 million for FY2025, which is 1118.15% down from last year.
  • InMed Pharmaceuticals' Cash from Operations amounted to -$2.4 million in Q4 2025, which was up 503.15% from -$1.6 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Cash from Operations ranged from a high of -$657934.0 in Q2 2023 and a low of -$5.3 million during Q1 2022
  • In the last 5 years, InMed Pharmaceuticals' Cash from Operations had a median value of -$2.1 million in 2023 and averaged -$2.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 8374.37% in 2023, then crashed by 7281.07% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Operations (Quarter) stood at -$3.5 million in 2021, then rose by 23.22% to -$2.7 million in 2022, then soared by 31.88% to -$1.8 million in 2023, then tumbled by 35.39% to -$2.5 million in 2024, then increased by 5.03% to -$2.4 million in 2025.
  • Its Cash from Operations was -$2.4 million in Q4 2025, compared to -$1.6 million in Q3 2025 and -$1.8 million in Q2 2025.